AldosteroneElsevier, 15 de fev. de 2019 - 300 páginas Aldosterone, Volume 109, the latest release in the Vitamins and Hormones series first published in 1943, covers the field of hormone action, vitamin action, X-ray crystal structure, physiology and enzyme mechanisms, with this release focusing on topics relating to Aldosterone Research, Aldosterone and Micrornas, the Evolution of the Mineralocorticoid Receptor, Aldosterone and Kidney Micrornas, Adipocyte Mineralocorticoid Receptor, Regulation of Aldosterone Secretion, Leptin and Aldosterone, Cell- and Ligand-Specific Interactions in Mineralocorticoid Receptor Signaling, Primary Aldosteronism, Present and Future, Aldosterone-Producing Adenomas, Overexpression of the Mineralocorticoid Receptor, Aldosterone and Myocardial Pathology, and much more.
|
Conteúdo
Contents | 18 |
The MR Consists of Multiple Functional Domains | 19 |
Diverse Steroids Have High Affinity for the MR | 26 |
16 | 31 |
Mechanisms of Mineralocorticoid Receptor Signaling | 37 |
Regulation of Aldosterone Signaling by MicroRNAs | 69 |
MiR Regulation of Aldosterone Signaling | 76 |
MiR Regulation of Other Kidney Transporters and Regulatory Proteins | 82 |
Inhibitors of Aldosterone Synthase | 211 |
Weldon and Nicholas F Brown 1 Aldosterone in Health and Disease | 212 |
Aldosterone Synthase Inhibitors | 215 |
The Next Generation of Aldosterone Synthase Inhibitors | 229 |
Summary and Conclusions | 232 |
Regulation of Aldosterone Secretion | 241 |
The ReninAngiotensin System | 247 |
Other Regulators of Aldosterone Secretion | 253 |
Acknowledgments | 93 |
Aldosterone and Ion Channels | 105 |
NonGenomic Effects of Aldosterone | 133 |
Mineralocorticoid Receptor Antagonists | 151 |
Anneli Nordqvist and Kenneth L Granberg 1 Clinical Use of Mineralocorticoid Receptor Antagonists | 152 |
Specific Challenges in Designing Mineralocorticoid Receptor Antagonists | 154 |
MR Antagonists That Fit in the Aldosterone Binding Site | 156 |
MR Antagonists That Utilize the Met852 Pocket | 158 |
The Helix 67 Induced Pocket | 170 |
Aromatic Sulfonamides as MR Antagonists | 171 |
Pyrrole Derivatives as MR Antagonists | 172 |
The 14Dihydropyridine Class of MR Antagonists | 174 |
The Pyrazoline Class of MR Antagonists | 177 |
Oxazolidinone Derivatives as MR Antagonists | 179 |
MR Antagonists With a Tricyclic Scaffold | 181 |
Summary | 182 |
Michael E Baker | 184 |
Adipocyte Mineralocorticoid Receptor | 189 |
The Adipose Organ | 190 |
Adipocyte Mineralocorticoid Receptor MR and Adipogenesis | 194 |
MR and Adipose Tissue Inflammation | 195 |
Relationship Between MR Signaling and Browning of WAT | 196 |
Novel Concepts Explaining the ObesityRelated Hyperaldosteronism | 198 |
Role of AldosteroneMR System in Metabolic Syndrome | 200 |
Use of MR Antagonists in Obesity and Metabolic Syndrome | 202 |
Conclusions | 203 |
Acknowledgments | 259 |
Leptin and Aldosterone | 265 |
Implications for the Sex Discrepant LeptinAldosterone Relationship | 272 |
Conclusion and Perspectives | 278 |
Present and Future | 285 |
The FuturePrevalence | 292 |
Primary aldosteronism PA for primary care practitioners PCPs | 298 |
Introduction | 304 |
Genomic and Nongenomic Signaling Pathways Activated Downstream | 387 |
AldoMR System | 391 |
From Cardiac Fibrosis to HF | 394 |
Targeting AldosteroneMRSignaling Pathway as a Novel Strategy to Treat HF Patients | 396 |
Conclusions | 398 |
400 | |
AldosteroneProducing Adenomas | 407 |
Introduction | 408 |
Epidemiology of PA | 409 |
Pathophysiology and Genetic Disturbances | 410 |
Low Renin HypertensionInappropriate Aldosterone Secretion | 420 |
SideEffects of PA | 421 |
Diagnostics | 422 |
Treatment | 424 |
Outcome | 425 |
Summary | 426 |